GE HealthCare is in advanced discussions to acquire Sofie Biosciences for approximately $1 billion, according to the Financial Times, a transaction that would expand the medical technology company’s presence in radiopharmaceutical diagnostics and strengthen its position beyond traditional medical imaging equipment.
Sofie Biosciences develops radiopharmaceuticals used with positron emission tomography, or PET, imaging to help physicians detect and evaluate diseases including cancer.
The company’s portfolio includes diagnostic agents intended to help identify conditions such as gastroesophageal and pancreatic cancer, giving GE HealthCare additional exposure to the pharmaceutical side of medical imaging.
The potential acquisition would complement GE HealthCare’s existing portfolio of imaging technologies, which includes MRI, CT and PET systems.
Rather than only supplying the equipment used to generate medical images, GE HealthCare has increasingly been building capabilities around the diagnostic agents and related technologies used inside those systems.
Acquiring Sofie would deepen that strategy by bringing additional radiopharmaceutical expertise directly into the company.
Radiopharmaceuticals are compounds containing radioactive isotopes that can be administered to patients and tracked using imaging systems such as PET scanners.
Different compounds can be designed to interact with particular biological processes or targets, potentially allowing physicians to visualize abnormal activity associated with diseases.
That makes the radiopharmaceutical itself an important part of the diagnostic process.
A PET scanner provides the imaging infrastructure, while the radiopharmaceutical determines what physicians can detect.
Owning capabilities across both areas could give GE HealthCare a more integrated position in molecular imaging.
The strategy also shifts more of the company’s exposure toward recurring consumable products.
Large imaging systems such as MRI, CT, and PET scanners represent significant capital investments for hospitals and healthcare providers, yet individual units can remain in service for years.
Diagnostic pharmaceutical products operate under a different business model because they are used repeatedly as patients undergo imaging procedures.
That creates the potential for a recurring revenue stream tied to procedure volumes rather than solely to new equipment installations.
For GE HealthCare, adding Sofie could therefore increase its participation in the economics surrounding each PET scan.
The company could potentially benefit not only when healthcare providers purchase imaging systems but also as those systems are used to perform diagnostic procedures.
The combination could also create strategic advantages in product development.
A company with expertise across scanners, imaging software and diagnostic agents may be able to coordinate development across the entire imaging workflow.
That could include optimizing equipment and software for specific radiopharmaceuticals or developing new diagnostic approaches that leverage advances across multiple technologies.
The potential acquisition comes as molecular imaging and precision diagnostics become increasingly important in cancer care.
Physicians are seeking more precise ways to determine where disease is located, how extensively it has spread and whether a patient is responding to treatment.
PET imaging can provide functional information about biological activity that complements the anatomical images generated by other technologies.
Radiopharmaceuticals play a central role in that process because different agents can target different biological characteristics.
That makes the development of new diagnostic tracers an important area of healthcare innovation.
For GE HealthCare, acquiring an established radiopharmaceutical company could provide a faster route to expanding those capabilities than building an equivalent portfolio entirely through internal research and development.
Sofie also brings specialized expertise in an area with significant operational complexity.
Radiopharmaceuticals can be more difficult to manufacture and distribute than conventional pharmaceuticals because radioactive isotopes decay over time.
That means production, logistics and delivery often need to be closely coordinated with healthcare providers and imaging schedules.
A company that has already built the infrastructure and expertise required to operate in that environment can therefore represent a strategically valuable acquisition target.
The approximately $1 billion potential purchase price would also represent a significant increase from Sofie’s previously reported valuation.
Sofie, which is backed by its founders and private equity firm Trilantic, was reportedly valued at as much as $550 million in 2024.
A transaction at $1 billion would value the t roughly 82% above the uppthe er end of that reported 2024 valuation.
The increase couup to both Sofie’s own development and growing strategic interest in radiopharmaceutical assets.
Medical technology and pharmaceutical companies have increasingly focused on areas where diagnostics can be paired more closely with therapeutic decision-making.
Advanced imaging can help physicians determine which patients may be suitable for particular treatments and track how disease responds.
That relationship could make diagnostic radiopharmaceutical platforms increasingly important as precision medicine expands.
For GE HealthCare, the deal would also represent another significant transaction since the company became independent from General Electric.
GE HealthCare separated from GE in 2023, creating a standalone medical technology company with greater flexibility to determine its own capital allocation, research priorities and acquisition strategy.
The Sofie transaction would reportedly become GE HealthCare’s second major acquisition since the separation.
That makes the potential purchase important not just because of its size but because it provides another indication of how management is reshaping the company’s portfolio as an independent business.
GE HealthCare has been evaluating where it can concentrate resources in businesses offering stronger long-term growth opportunities.
Radiopharmaceutical diagnostics fit that broader objective because they sit at the intersection of imaging technology, pharmaceuticals and precision medicine.
Sofie’s platform could strengthen an area where GE HealthCare already has substantial commercial relationships.
Hospitals, imaging centers and other healthcare providers using GE HealthCare PET systems could potentially represent customers for complementary diagnostic agents.
Likewise, a broader radiopharmaceutical portfolio could strengthen the strategic value of GE HealthCare’s imaging equipment by providing customers with more integrated diagnostic capabilities.
The acquisition could therefore create opportunities for cross-selling, although the companies have not publicly disclosed specific revenue or cost synergies.
The transaction would also deepen GE HealthCare’s exposure to oncology.
Cancer diagnosis and monitoring account for significant use of advanced imaging technologies, and developing more targeted diagnostic products could allow the company to participate in additional parts of the oncology care pathway.
Diagnostic radiopharmaceuticals may help physicians identify tumors, evaluate disease progression and determine how patients are responding to therapy.
That information can influence treatment decisions and potentially improve the ability to personalize care.
Sofie would give GE HealthCare additional assets specifically designed around those diagnostic applications.
From a portfolio perspective, the transaction could make GE HealthCare less dependent on the capital-equipment cycle.
Demand for expensive imaging systems can fluctuate depending on hospital budgets, financing conditions and healthcare capital spending.
Pharmaceutical diagnostics can provide a different source of revenue that is more closely connected to procedure volumes.
Expanding that portion of the business could therefore increase the diversity of GE HealthCare’s revenue streams.
The potential deal also illustrates how medical imaging is evolving from a hardware-centered market toward a broader combination of equipment, software, artificial intelligence and specialized diagnostic agents.
Improvements in scanner hardware remain important, but healthcare providers are increasingly looking for technologies that improve the information extracted from each procedure.
Radiopharmaceuticals can enhance that information by making specific biological processes visible.
Artificial intelligence and advanced image analysis can then potentially help clinicians interpret increasingly complex imaging data.
GE HealthCare’s ability to participate across several of those layers could strengthen its competitive position.
The company already operates across medical imaging and related technologies, and Sofie’s radiopharmaceutical portfolio would add another component to that ecosystem.
However, discussions remain ongoing, and there is no guarantee that an acquisition will ultimately be completed.
The final transaction value or terms could also change before an agreement is announced.
If GE HealthCare does reach a deal at approximately $1 billion, the acquisition would represent a sizable strategic investment in molecular imaging and pharmaceutical diagnostics.
The transaction would give GE HealthCare additional radiopharmaceutical assets, deepen its oncology exposure and provide a stronger connection between the company’s imaging hardware and the agents used during PET procedures.
For Sofie’s investors, a sale near $1 billion would also represent a substantial increase from the company’s reported valuation of up to $550 million in 2024.
More broadly, the potential acquisition demonstrates how GE HealthCare is using its independence from General Electric to selectively reshape its portfolio around areas where medical devices, pharmaceuticals and precision diagnostics increasingly converge.
If completed, Sofie could become an important part of that strategy by expanding GE HealthCare from a major supplier of medical-imaging equipment into a more integrated provider of the technologies and diagnostic agents used throughout the imaging process.
